Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

AIDS

Volumn 13, Issue 15, 1999, Pages 2061-2068

  Race, Esther ^a   Dam, Elizabeth ^a   Obry, Veronique ^a   Paulous, Sylvie ^b   Clavel, François ^a  

^a BICHAT HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Cross resistance; HIV drug resistance; Phenotypic assay; Protease inhibitors

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS ENZYME;

ARTICLE; CROSS RESISTANCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHENOTYPE; TREATMENT FAILURE;

EID: 0032750954     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00008     Document Type: Article

References (43)

1. Collier A, Coombs R, Schoenfeld D, et al. Treatment of HIV infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
2. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
3. Notermans DW, Jurriaans S, de Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 1998, 12:167-173.
4. Ruiz L, van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999, 13:F1-F8.
5. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to a HIV-1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996, 173:1-9.
6. Condra J, Holder D, Schlief W, et al. Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor. J Virol 1996, 70:8270-8276.
7. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997, 94:12574-12579.
8. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
9. Craig C, Race E, Sheldon J, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998, 12:1611-1618.
10. Cox SW, Aperia K, Sandstrom E, et al. Cross-resistance between AZT, ddl and other antiretroviral drugs in primary isolates of HIV-1. Antiviral Chem Chemother 1994, 5:7-12.
11. Miller V, de Bethune MP, Kober A, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998, 42:3123-129.
12. Schmit JC, van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998, 12:2007-2015.
13. Schmit JC, Weber B. Recent advances in antiretroviral therapy and HIV infection monitoring. Intervirology 1997, 40:304-321.
14. Vandamme AM, van Vaerenbergh K, de Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 1998, 9:187-203.
15. Deeks SC, Parkin N, Petropôulos CJ, et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patietns who failed indinavir therapy. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore. Italy, June 1998 [abstact 53].
16. Leigh Brown A, D'Aquilla RT, Johnson VA, Kurizkes DR, Richman DD. Baseline sequence clusters predict response to combination therapy in ACTG 241. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstact 50].
17. Zolopa AR, Shafer RW, Warford A, et al. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 54].
18. Harrigan PR, Montaner JS, Hogg RS, et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstact 55].
19. Lorenzi P, Opravil M, Hirschel B, et al. Impact of resistance mutations on virologic response to salvage therapy. AIDS 1999, 13:F17-F21.
20. Goulden MG, Cammack N, Hopewell PL, Penn CR, Cameron JM. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine [letter]. AIDS 1996, 10:101-102.
21. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
22. de Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997, 176:899-903.
23. Nijhuis M, Schuurman R, de jong D, et al. Lamivudine-resistant HIV-1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo J Infect Dis 1997, 176:398-405.
24. Kemp SD, Shi C, Bloor S, et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998, 72:5093-5098.
25. de Jong JJ, Goudsmit J, Lukashov V, et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogues. AIDS 1999, 13:75-80.
26. Markland W, Zuchowski L, Black J, et al. Kinetic analysis of HIV-1 protease mutations: amprenavir resistance, cross-resistance and resensitization. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 24].
27. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996, 2:760-766.
28. Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem 1996, 271:31957-1963.
29. Race E, Gilbert SM, Sheldon JG, et al. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS 1998, 12:1465-1474.
30. Dulioust A, Paulous S, Guillemot L, et al. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999, 73:850-854.
31. Kellam P, Larder B. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of HIV-1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
32. Boucher C, Keulen W, Bommel T, et al. HIV-1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996, 40:2404-2409.
33. Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother 1997, 41:2781-2785.
34. Hertogs K, de Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
35. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
36. Medina DJ, Tung PP, Nelson CJ, et al. Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV. J Virol Meth 1998, 71:169-176.
37. Chameau P, Mirambeau G, Roux P, et al. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994, 241:651-662.
38. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998, 72:3300-3306.
39. Eustice D, Feldman P, Colberg-Poley A, Buckery R, Neubauer R. A sensitive method for the detection of β-galactisidase in transfected mammailian cells. BioTechniques 1991, 11:739-743.
40. Chou T-C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy. Edited by Chou T-C, Rideout J. Academic Press, New York; 1991:61-102.
41. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997, 5:129-137.
42. Hertogs K, Kemp S, Bloor S, et al. Patterns of cross-resistance amoung protease inhibitors in over 1500 clinical isolates. Comparison of genotypic and phenotypic resistance profiles. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstact 70].
43. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997, 71:6662-6670.